The Blog

We launched the first version of AVD Clinical in January 2026 with three things: a resource library, a budget calculator, and a set of original SOPs. This is what's changed since then.

What shipped in Q2

• Medicine Reminders — a free, encrypted personal medication reminder tool. You enter your own medications; the data stays on your account, protected by row-level security, never shared. This is the first feature that is not a document download or a calculator — it's a light daily-use tool. No PHI accepted.
• Expanded SOP library — 25+ templates now available, including bundles for site startup, monitoring, QA, closeout, PHI handling, inspection readiness, validation, sponsor/CRO oversight, patient-facing workflows, and budget planning.
• Revised pricing — the Calculator moved to $19/month unlimited (or $149/year), with a $9 single report option. We removed the confusing "lifetime" tier that was causing mismatched expectations.
• New legal pages — we rewrote the Privacy Policy and Terms of Service to cover every product we actually offer (not just the library), added a proper Template License (EULA), a HIPAA & PHI Notice, a Refund Policy, and a Security page. The footer on every page now links to all of them.
• Platform Roadmap section — the homepage feature grid now shows a live/coming soon/enterprise roadmap label on every card, so you know exactly what you can use today versus what's planned.

What we changed based on feedback

A few things that looked fine in testing didn't hold up in practice. The calculator paywall was blocking the mode-switch tabs — that's fixed. Paid buttons weren't real links for crawlers — that's fixed. The homepage claimed features like AI eConsent and wearable integration as if they were live; they're now clearly labeled as Enterprise Roadmap items.

What's next

Role-based clinical accounts (investigator, sub-I, coordinator, pharmacist) with license verification are in design. AI-assisted SOP generation is in development. Certifications and on-demand courses are planned for Q4. We'll update here as things ship rather than on a forced monthly cadence.

Decentralized clinical trial (DCT) approaches — remote consent, home nursing visits, direct-to-patient drug shipment, wearable ePRO — went from novel to expected between 2020 and 2023. By 2025, most protocols at large sponsors included at least one DCT element. The question now is whether those elements are actually delivering on the original promise.

What's working

Remote consent and pre-screening have had the most consistent positive evidence. Sites using digital pre-screening funnels (not AI matching — just structured online eligibility forms) are reporting 20–35% reductions in screen failure at first visit, because patients who arrive already understand the eligibility criteria. That's real and reproducible.

Direct-to-patient drug shipment works well in low-complexity, oral medication trials. It reduces the burden on patients who would otherwise need to travel to site for drug pickup. The pharmacy logistics are manageable when the drug is stable and the patient monitoring requirements are light.

What isn't working as expected

Wearable ePRO sounds compelling in the protocol but creates real data quality headaches. Compliance rates drop sharply after week four. The data streams are large and require cleaning infrastructure most sites don't have. Regulatory acceptance of wearable-derived endpoints remains inconsistent across FDA and EMA. Most sponsors who've run a wearable-heavy trial once are more cautious the second time.

Home nursing visits are expensive, logistically complex, and harder to quality-assure than anticipated. The cost per visit is often higher than bringing the patient to site, and the audit trail requirements for home visits are stricter than many vendors initially communicated.

Full decentralization — where there is no site at all — has not proven viable for most indications. The FDA's 2023 DCT guidance was clear that removing the investigator from clinical oversight entirely creates problems that technology doesn't solve.

Where this lands for site teams

The most effective DCT implementations have been hybrid: keep the investigator relationship and the site as the anchor, add remote elements for visits that don't require in-person assessment. This is what the ICH E6(R3) risk-based framework actually supports — fit your monitoring intensity to the risk of the activity, not to an ideology about remote vs. in-person.

For coordinators and CRAs, the practical implication is that your SOPs and monitoring plans need to explicitly address which visits are eligible for remote conduct, what the audit trail requirements are for those visits, and how you handle a patient who loses connectivity or doesn't respond to remote prompts.

The R3 revision dropped in 2024 and replaced the R2 integrated addendum from 2016. Most coverage focused on the structural changes — the document is now organized differently with clearer principles vs. annexes — but the operational impact lands at three specific places in site work.

1. Quality by Design becomes a documented requirement

Under R2, "quality by design" was an aspirational concept. Under R3, sites are expected to document how their procedures are designed to prevent the most likely errors before they happen, not just detect them after. For most sites this means revising your site SOP for protocol training to include an explicit risk discussion at the SIV — not just a topic checklist.

2. Risk-based monitoring is now expected, not optional

Sponsors operating under E6(R3) are expected to implement risk-based monitoring. This pushes pressure down to sites: full SDV across every data point is no longer the default. Sites need to be ready for monitoring visits that focus on critical data and processes rather than line-by-line review.

3. Electronic systems get sharper requirements

R3 tightens the language around electronic data — audit trails, validated systems, controlled access. If your site uses a paper-electronic hybrid (still common in academic settings), you'll need to be explicit about which is the source of truth for each data point.

What to do today

• Review your site Quality Manual against the R3 quality-by-design language and update if needed
• Update protocol training documentation to capture risk discussion explicitly (not just topic checklists)
• Audit your hybrid paper-electronic workflows and document which is the source of truth per data element
• If you use validated electronic systems, confirm audit trail completeness against R3 expectations

TransCelerate BioPharma is an industry consortium of major pharma companies that publishes harmonized templates and frameworks for clinical research — the Common Protocol Template, the Common Clinical Study Report Template, the Risk Assessment and Categorization Tool, the SIV Toolkit, and many more. They are excellent. They are also dense.

The single most useful skill

Most TransCelerate documents are written for committee consensus, not first-time readers. The actual operational instructions are buried inside long preambles explaining who the consortium is and why the template exists. Skip the preamble. Jump directly to the section labeled "Instructions for Use" or "User Guide" — that's where the actionable content lives.

How to use a TransCelerate template effectively

• Don't fill it in directly. Save a copy under your sponsor name and modify there. The original stays as a reference point.
• Track your changes vs. the source. When auditors ask why a clause differs from the standard template, you need to know.
• Local regulatory adjustments come last. Fill out the standard sections first, then add country/state-specific addenda at the end rather than modifying the body.
• Read the change log. TransCelerate revises templates regularly. The change log at the front tells you what's new since the version you used last.

The templates worth knowing first

If you only learn three TransCelerate templates well, make them: the Common Protocol Template, the Risk Assessment and Categorization Tool, and the Investigator Site Files Reference Model. These three cover the majority of inspection-relevant work at sites and CROs.

Clinical research has too many tools that promise everything and deliver nothing. We're trying not to be one of them. Here's where we actually are.

Live today

• Resource Library — curated regulatory templates with AVD commentary on each one. Free, with one-time sign-up.
• AI Budget Calculator — sponsor and site-level estimation modes. First calculation free.
• Original AVD SOPs — 25 starting frameworks covering site, CRO, and sponsor activities.

What's next

• More SOPs as common requests come in
• Calculator scenario comparison and PDF report exports
• Monthly newsletter on regulatory changes and platform progress

The platform vision (longer-term)

Basic email OTP sign-in is live today for Library downloads and Calculator access. The fuller platform vision — role-based clinical accounts, license verification, donation matching, regulated workflow dashboards, and audit logs — requires validated backend infrastructure and a development team. We are NOT going to fake those features while we build them.

What we're not building

• A clinical trial recruitment site — we don't enroll patients
• An EMR/EHR integration product — that's a Phase 5+ effort
• An AI clinical decision support tool — that's Software as a Medical Device territory

We'd rather have a small set of things that work than a big set of things that don't.